ZENAS BIOPHARMA INC (ZBIO) — insider trading
Health Care · NASDAQ
ZENAS BIOPHARMA INC (ZBIO) has 17 reported SEC Form 4 insider transactions in our data, including 4 open-market purchases among the most recent 17 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Oliger Christy J. | Director | Grant / award / vesting (derivative) | 37,000 | — | $0 | Form 4 |
| 2026-06-15 | Fox Jennifer A. | Officer (See Remarks) | Grant / award / vesting (derivative) | 125,000 | — | $0 | Form 4 |
| 2026-06-15 | Farmer Joseph L | Officer (See Remarks) | Grant / award / vesting (derivative) | 175,000 | — | $0 | Form 4 |
| 2026-06-15 | ENRIGHT PATRICK G | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-06-15 | Boylan James P | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-06-15 | Allen Patricia L | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-06-15 | von Moltke Lisa | Officer (See Remarks) | Grant / award / vesting (derivative) | 150,000 | — | $0 | Form 4 |
| 2026-06-15 | ORLOFF JOHN J | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-06-15 | MOULDER LEON O JR | Director, Officer (See Remarks) | Grant / award / vesting (derivative) | 500,000 | — | $0 | Form 4 |
| 2026-06-15 | Lu Hongbo | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-06-15 | Nunn Jason Raleigh | Director | Grant / award / vesting (derivative) | 18,500 | — | $0 | Form 4 |
| 2026-05-18 | MOULDER LEON O JR | Director, Officer (Chief Executive Officer) | Open-market purchase | 60,000 | $16.88 | $1.01M | Form 4 |
| 2026-04-29 | MOULDER LEON O JR | Director, Officer (Chief Executive Officer) | Open-market purchase | 35,000 | $17.62 | $616.7K | Form 4 |
| 2026-04-28 | MOULDER LEON O JR | Director, Officer (Chief Executive Officer) | Open-market purchase | 25,000 | $18.02 | $450.5K | Form 4 |
| 2026-03-31 | Lu Hongbo | Director | Open-market purchase | 3,768 | $18.63 | $70.2K | Form 4 |
| 2026-02-05 | Fox Jennifer A. | Officer (See Remarks) | Grant / award / vesting | 1,592 | $13.35 | $21.3K | Form 4 |
| 2026-02-05 | Farmer Joseph L | Officer (See Remarks) | Grant / award / vesting | 974 | $13.35 | $13.0K | Form 4 |
Ask the chat about ZBIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ZENAS BIOPHARMA INC (ZBIO).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.